Chia‐Ing Jan et al treated 27 tumor antigen‐DC patients with GBM and found patients whose tumor‐infiltrating lymphocytes (TIL) with a lower PD‐1+/CD8+ ratio (>0.21) have a longer OS and PFS (median P S 60.97 months, p < 0.001 and PFS 11.08 months) (p < 0.008 months).74 This evidence concerns the gene CD8A and neoplasm.